Jin‐Hee Ahn

2.7k total citations
115 papers, 1.9k citations indexed

About

Jin‐Hee Ahn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jin‐Hee Ahn has authored 115 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 37 papers in Cancer Research. Recurrent topics in Jin‐Hee Ahn's work include Cancer Treatment and Pharmacology (28 papers), Breast Cancer Treatment Studies (25 papers) and HER2/EGFR in Cancer Research (22 papers). Jin‐Hee Ahn is often cited by papers focused on Cancer Treatment and Pharmacology (28 papers), Breast Cancer Treatment Studies (25 papers) and HER2/EGFR in Cancer Research (22 papers). Jin‐Hee Ahn collaborates with scholars based in South Korea, United States and Japan. Jin‐Hee Ahn's co-authors include Sung‐Bae Kim, Gyungyub Gong, Hanjong Ahn, Hee Jin Lee, Jun Hyuk Hong, Jae‐Lyun Lee, Woo Kun Kim, Kyung Hae Jung, Cheryn Song and Sung Sook Lee and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Jin‐Hee Ahn

112 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jin‐Hee Ahn South Korea	25	938	821	549	484	323	115	1.9k
Jinming Yu China	19	1.2k 1.3×	671 0.8×	579 1.1×	456 0.9×	285 0.9×	66	2.3k
Zhimin Shao China	22	1.1k 1.2×	557 0.7×	516 0.9×	557 1.2×	150 0.5×	90	1.8k
Hirofumi Uehara Japan	22	805 0.9×	1.2k 1.5×	888 1.6×	665 1.4×	300 0.9×	79	2.2k
Panagiotis J. Vlachostergios United States	21	616 0.7×	683 0.8×	602 1.1×	370 0.8×	182 0.6×	109	1.6k
Arlene Berman United States	22	1.3k 1.4×	474 0.6×	614 1.1×	534 1.1×	165 0.5×	47	2.4k
Andreas H. Marx Germany	26	1.3k 1.4×	822 1.0×	698 1.3×	301 0.6×	583 1.8×	75	2.2k
Anas Gazzah France	22	1.3k 1.4×	861 1.0×	553 1.0×	355 0.7×	259 0.8×	99	2.1k
Séverine Guiu France	24	1.1k 1.2×	464 0.6×	399 0.7×	751 1.6×	131 0.4×	78	1.9k
Jianming Guo China	26	869 0.9×	914 1.1×	1.3k 2.4×	547 1.1×	532 1.6×	181	2.7k
David Garfield United States	22	1.1k 1.1×	1.2k 1.4×	769 1.4×	622 1.3×	273 0.8×	52	2.4k

Countries citing papers authored by Jin‐Hee Ahn

Since Specialization

Citations

This map shows the geographic impact of Jin‐Hee Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin‐Hee Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin‐Hee Ahn more than expected).

Fields of papers citing papers by Jin‐Hee Ahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin‐Hee Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin‐Hee Ahn. The network helps show where Jin‐Hee Ahn may publish in the future.

Co-authorship network of co-authors of Jin‐Hee Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Jin‐Hee Ahn. A scholar is included among the top collaborators of Jin‐Hee Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin‐Hee Ahn. Jin‐Hee Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Young Joo, Tae-Kyung Yoo, Sae Byul Lee, et al.. (2025). Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome Among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Journal of Breast Cancer. 28(1). 11–11.

Ahn, Jin‐Hee, Jeeyun Lee, Changhee Park, et al.. (2024). Clinical Activity of TGF-β Inhibitor Vactosertib in Combination with Imatinib in Desmoid Tumors: A Multicenter Phase Ib/II Study. Clinical Cancer Research. 30(8). 1457–1465. 13 indexed citations

Hyung, Jaewon, Shinkyo Yoon, Changhoon Yoo, et al.. (2023). Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis. ESMO Open. 8(3). 101583–101583. 2 indexed citations

Kim, Chang Gon, Nam Suk Sim, Jeong Eun Kim, et al.. (2022). Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. Clinical Cancer Research. 28(15). 3225–3234. 6 indexed citations

Jeong, Jae Ho, et al.. (2021). CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience. Journal of Breast Cancer. 25(1). 49–49. 3 indexed citations

Choi, Jungmin, et al.. (2021). Targeted mutagenesis in mouse cells and embryos using an enhanced prime editor. Genome biology. 22(1). 170–170. 94 indexed citations

Kim, Jee Hung, So Hun Kim, Hei‐Cheul Jeung, et al.. (2021). Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial. ESMO Open. 6(5). 100249–100249. 2 indexed citations

Kim, Yeon Joo, Su Ssan Kim, Seung Do Ahn, et al.. (2020). The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. Asia-Pacific Journal of Clinical Oncology. 17(6). 495–505. 4 indexed citations

Kim, Ji‐Yeon, Seri Park, Seock‐Ah Im, et al.. (2019). Quality of life outcomes including neuropathy‐associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first‐line chemotherapy for HER2‐negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13‐11). Cancer Communications. 39(1). 29–29. 3 indexed citations

10.

Choi, Woo Jung, Hee Jung Shin, Eun Young Chae, et al.. (2017). Long-term Survival Outcomes of Primary Breast Cancer in Women With or Without Preoperative Magnetic Resonance Imaging: A Matched Cohort Study. Clinical Oncology. 29(10). 653–661. 18 indexed citations

11.

Koh, Young Wha, Hee Jin Lee, Jin‐Hee Ahn, Jong Won Lee, & Gyungyub Gong. (2014). Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biology. 35(10). 9823–9830. 56 indexed citations

12.

Lee, Hee Jin, An Na Seo, So Yeon Park, et al.. (2014). Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets. Annals of Surgical Oncology. 21(5). 1561–1568. 52 indexed citations

13.

Park, Inkeun, Kwonoh Park, Seongjoon Park, et al.. (2013). Response Evaluation Criteria in Solid Tumors Response of the Primary Lesion in Metastatic Renal Cell Carcinomas Treated With Sunitinib: Does the Primary Lesion Have to Be Regarded as a Target Lesion?. Clinical Genitourinary Cancer. 11(3). 276–282. 2 indexed citations

14.

Shin, Hee Jung, Hyeon‐Man Baek, Jin‐Hee Ahn, et al.. (2012). Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion‐weighted imaging and MRS. NMR in Biomedicine. 25(12). 1349–1359. 55 indexed citations

15.

Jang, Geundoo, Sung Sook Lee, Jin‐Hee Ahn, et al.. (2011). Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Research and Treatment. 128(1). 171–177. 19 indexed citations

16.

Im, Seock‐Ah, Keun Seok Lee, Jungsil Ro, et al.. (2011). Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01. Breast Cancer Research and Treatment. 132(2). 589–600. 9 indexed citations

17.

Lee, Jae‐Lyun, Jin‐Hee Ahn, Se Hoon Park, et al.. (2011). Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Investigational New Drugs. 30(5). 1984–1990. 52 indexed citations

18.

Lee, Sung Sook, Jin‐Hee Ahn, Min Kyoung Kim, et al.. (2007). Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Research and Treatment. 111(3). 523–530. 126 indexed citations

19.

Lee, Sung Sook, Min Kyoung Kim, Sun Jin Sym, et al.. (2007). Intramedullary spinal cord metastases: a single-institution experience. Journal of Neuro-Oncology. 84(1). 85–89. 79 indexed citations

20.

Ahn, Jin‐Hee, et al.. (2005). Systemic adjuvant therapy in breast cancer. The Korean Journal of Internal Medicine. 69(3). 243–254. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact